Geron Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp.

GERN 1.170

-1.7%

Nov 28 12:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Savant who wrote (2759)	2/13/2004 4:09:05 PM
From: JMarcus	Read Replies (2) of 3576

From today's SF Chronicle: <<Thomas Okarma, chief executive of Geron Corp. of Menlo Park, a widely acknowledged leader in embryonic stem cells, said his company hoped to file for approval of a clinical trial in 2005, using cells derived from embryonic stem cells to treat spinal cord injuries. Such treatment has restored mobility in some paralyzed rats, he said. "We've gone way beyond the academic world and where most of the pundits think the field is," Okarma said. Geron does not do therapeutic cloning but uses human embryonic stem cells derived from embryos left over from fertility clinics, created by the fertilization of egg by sperm. >> sfgate.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next